Last reviewed · How we verify

NCT06562036

Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children

Completed NA Last updated 26 August 2024
What this trial tests

NA trial testing Sildenafil in Persistent Pulmonary Hypertension of the Newborn in 42 participants. Completed in 31 May 2024.

Timeline
1 December 2023
Primary endpoint
31 May 2024
31 May 2024

Quick facts

Lead sponsorMuhammad Aamir Latif
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment42
Start date1 December 2023
Primary completion31 May 2024
Estimated completion31 May 2024
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Muhammad Aamir Latif — full company profile →

Who can join

Adults 1 Day to 28 Days, any sex, with Persistent Pulmonary Hypertension of the Newborn. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Neonates with persistent pulmonary hypertension (PPH) should be administered inhaled nitric oxide (iNO) and extracorporeal membrane oxygenation (ECMO), but these are not available in most resource-constrained settings like ours. This study was planned to compare the outcomes of Milrinone plus Sildenafil versus Sildenafil alone in the treatment of PPH in neonates.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sildenafil

Trials testing the same drug.

Other recruiting trials for Persistent Pulmonary Hypertension of the Newborn

Currently open trials in the same condition.

Other Muhammad Aamir Latif trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06562036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing